MIGENIX Reports Effectiveness of MX-2401 in Pneumonia Model
MIGENIX Inc., a clinical-stage developer of drugs for infectious and degenerative diseases, has obtained positive results on the effectiveness of its lipopeptide anti-bacterial product candidate, MX-2401, in accepted experimental models of pneumonia and soft tissue infections. This injectable compound is in preclinical development for the treatment of serious gram- positive infections. The company recently received a $9.3 million investment commitment from the Government of Canada's Technology Partnerships Canada program towards the development of MX-2401
In studies conducted by Dr. William Craig at the University of Wisconsin Medical School and the VA Medical Center, the ability of MX-2401 to kill Streptococcus pneumoniae in the lungs and/or thighs of infected mice (a model used widely to predict efficacy in human pneumonia and complicated skin and soft tissue infections) and the efficacy of MX-2401 against another serious gram-positive pathogen, Staphylococcus aureus were confirmed. Dr. Craig is an internationally recognized expert in anti-infective therapy and Head of Clinical Pharmacology at the University of Wisconsin Medical School and a member of the MIGENIX Clinical Advisory Board.
Other news from the department research and development
